Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2023

Open Access 01-12-2023 | Radioiodine Therapy | Study protocol

The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial

Authors: Sepide Amini, Marjan Golshani, Masoud Moslehi, Somayeh Hajiahmadi, Gholamreza Askari, Bijan Iraj, Mohammad Bagherniya

Published in: Trials | Issue 1/2023

Login to get access

Abstract

Background

Thyroid cancer is a very damaging disease. The most common treatment for this disease includes thyroidectomy and then using radioactive iodine (RAI). RAI has many side effects, including a decrease in salivary secretions, followed by dry mouth and oral and dental injuries, as well as increased inflammation and oxidative stress. Selenium can be effective in these patients by improving inflammation and oxidative stress and by modulating salivary secretions. So far, only one clinical trial has investigated the effect of selenium on thyroid cancer patients treated with radioiodine therapy (RIT) conducted on 16 patients; considering the importance of this issue, to show the potential efficacy of selenium in these patients, more high-quality trials with a larger sample size are warranted.

Methods

This is a parallel double-blind randomized controlled clinical trial that includes 60 patients aged 20 to 65 years with papillary thyroid cancer (PTC) treated with RAI and will be conducted in Seyyed al-Shohada Center, an academic center for referral of patients to receive iodine, Isfahan, Iran. Thirty patients will receive 200 µg of selenium for 10 days (3 days before to 6 days after RAI treatment) and another 30 patients will receive a placebo for the same period. Sonographic findings of major salivary glands, salivary secretions, and sense of taste will be evaluated before and 6 months after 10-day supplementation.

Discussion

Due to its anti-inflammatory and antioxidant effects, as well as improving salivary secretions, selenium may improve the symptoms of thyroid cancer treated with radioactive iodine. In past studies, selenium consumption has not reduced the therapeutic effects of radiation therapy, and at a dose of 300 to 500 μg/day, it has not had any significant side effects in many types of cancer under radiation therapy.

Trial registration

Iranian Registry of Clinical Trials IRCT202011290495​34N6. Registered on 16 September 2021.
Appendix
Available only for authorised users
Literature
1.
Bikas A, Burman KD. Epidemiology of thyroid cancer. Springer; 2019. p. 541–7.
2.
Younis E. Oncogenesis of thyroid cancer. Asian Pacific J Cancer Prev. 2017;18(5):1191-.
3.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. 2020;11:102-.
4.
Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer. Ann Clin Pathol. 2015;3(1):1045-.
5.
Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17–29.PubMed
6.
Fiore M, Oliveri Conti G, Caltabiano R, Buffone A, Zuccarello P, Cormaci L, et al. Role of emerging environmental risk factors in thyroid cancer: a brief review. Int J Environ Res Public Health. 2019;16(7):1185-.PubMedPubMedCentral
7.
Youssef MR, Reisner ASC, Attia AS, Hussein MH, Omar M, LaRussa A, et al. Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer–Pooled results of 24 million cohorts. Oral Oncol. 2021;112:105085-.PubMed
8.
Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, et al. Immune and inflammatory cells in thyroid cancer microenvironment. Int J Mol Sci. 2019;20(18):4413-.PubMedPubMedCentral
9.
Muzza M, Degl’Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol. 2010;72(5):702–8.
10.
Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol. 2010;321(1):94–102.PubMed
11.
Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176–88.PubMed
12.
Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci. 2019;21(1):10-.PubMedPubMedCentral
13.
Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. American Health Drug Benefits. 2015;8(1):30-.PubMedPubMedCentral
14.
Le Roux MK, Graillon N, Guyot L, Taieb D, Galli P, Godio-Raboutet Y, et al. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: long-term study. Head Neck. 2020;42(11):3133–40.PubMed
15.
Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR. Salivary evaluation in radioactive I131 treated patients with thyroid carcinoma. Acta Odontol Scand. 2018;76(2):148–52.PubMed
16.
Moreddu E, Baumstarck-Barrau K, Gabriel S, Fakhry N, Sebag F, Mundler O, et al. Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire. Br J Oral Maxillofac Surg. 2017;55(6):609–12.PubMed
17.
Wu J-q, Feng H-j, Ouyang W, Sun Y-g, Chen P, Wang J, et al. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Nuclear Med Commun. 2015;36(8):819–26.
18.
Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013;23(5):617–9.PubMed
19.
Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009;50(10):1605–10.PubMed
20.
BaDam RK, Suram J, Babu DBG, Waghray S, Marshal R, Bontha SC, et al. Assessment of salivary gland function using salivary scintigraphy in pre and post radioactive iodine therapy in diagnosed thyroid carcinoma patients. J Clin Diagnostic Res. 2016;10(1):ZC60-ZC.
21.
Lee HN, An JY, Lee KM, Kim EJ, Choi WS, Kim DY. Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose. Clin Imaging. 2015;39(3):396–400.PubMed
22.
Dingle IF, Mishoe AE, Nguyen SA, Overton LJ, Gillespie MB. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2013;148(5):746–52.PubMed
23.
Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol. 2007;19(1):83–6.
24.
Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13(3):265–71.PubMed
25.
Sengoz T, Kilic-Toprak E, Yaylali O, Kilic-Erkek O, Ozdemir Y, Oymak B, et al. Hemorheology and oxidative stress in patients with differentiated thyroid cancer following I-131 ablation/metastasis treatment. Clin Hemorheol Microcirc. 2020;74(2):209–21.PubMed
26.
Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808–17.PubMed
27.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.PubMed
28.
Kulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun. 2014;35(2):210–6.PubMed
29.
Gorini F, Sabatino L, Pingitore A, Vassalle C. Selenium: an element of life essential for thyroid function. Molecules. 2021;26(23):7084-.PubMedPubMedCentral
30.
Winther KH, Rayman MP, Bonnema SJ, Hegedüs L. Selenium in thyroid disorders—essential knowledge for clinicians. Nat Rev Endocrinol. 2020;16(3):165–76.PubMed
31.
32.
Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol. 2012;8(3):160–71.
33.
Gheorghiu ML, Badiu C. Selenium involvement in mitochondrial function in thyroid disorders. Hormones. 2020;19(1):25–30.PubMed
34.
de Oliveira MM, Batista BAM, Sousa MP, de Souza LM, Maia CSC. Selenium and thyroid cancer: a systematic review. Nutr Cancer. 2020;72(8):1255–63.
35.
O’Grady TJ, Kitahara CM, DiRienzo AG, Gates MA. The association between selenium and other micronutrients and thyroid cancer incidence in the NIH-AARP Diet and Health Study. PLoS One. 2014;9(10):e110886-e.
36.
Kato MA, Finley DJ, Lubitz CC, Zhu B, Moo T-A, Loeven MR, et al. Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34. Nutr Cancer. 2009;62(1):66–73.
37.
Duntas LH. The role of selenium in thyroid autoimmunity and cancer. Thyroid. 2006;16(5):455–60.PubMed
38.
Lee SM, Md RGY, Lee H, Md IL, Soon Kim M, Chung WY. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med. 2017;20:62–70.PubMed
39.
Schrauzer GN. Nutritional selenium supplements: product types, quality, and safety. J Am Coll Nutr. 2001;20(1):1–4.PubMed
40.
Huang Z, Chen Y, Pan L, Feng H, Wu J, Chen P, et al. Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study. Ultrasound Med Biol. 2021;47(9):2514–22.PubMed
41.
Choi J-S, Hong SB, Hyun IY, Lim J-Y, Kim Y-M. Effects of salivary secretion stimulation on the treatment of chronic radioactive iodine-induced sialadenitis. Thyroid. 2015;25(7):839–45.PubMed
42.
Freitas R, Nogueira RJN, Cozzolino SMF, Vasques ACJ, Hessel G. Influence of selenium supplementation on patients with inflammation: A pilot double blind randomized study. Nutrition (Burbank, Los Angeles County, Calif). 2017;41:32–6.PubMed
43.
Handa E, Puspitasari IM, Abdulah R, Yamazaki C, Kameo S, Nakano T, et al. Recent advances in clinical studies of selenium supplementation in radiotherapy. J Trace Elements Med Biol. 2020;62:126653-.
44.
Muecke R, Micke O, Schomburg L, Buentzel J, Kisters K, Adamietz IA, et al. Selenium in radiation oncology—15 years of experiences in Germany. Nutrients. 2018;10(4):483-.PubMedPubMedCentral
45.
Buczyńska A, Sidorkiewicz I, Rogucki M, Siewko K, Adamska A, Kościuszko M, et al. Oxidative stress and radioiodine treatment of differentiated thyroid cancer. Sci Rep. 2021;11(1):1–10.
46.
Zhang Z, Xu T, Qin W, Huang B, Chen W, Li S, et al. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer. Biochem Biophys Res Commun. 2020;522(1):21–5.PubMed
47.
El Hassani RA, Buffet C, Leboulleux S, Dupuy C. Oxidative stress in thyroid carcinomas: biological and clinical significance. Endocr Relat Cancer. 2019;26(3):R131–43.
48.
Xing M. Oxidative stress: a new risk factor for thyroid cancer. Endoc Related Cancer. 2012;19(1):C7-C.
49.
Letavayová L, Vlčková V, Brozmanová J. Selenium: from cancer prevention to DNA damage. Toxicology. 2006;227(1–2):1–14.PubMed
50.
Bhuyan AK, Sarma D, Saikia UK. Selenium and the thyroid: a close-knit connection. Indian J Endocrinol Metab. 2012;16(Suppl 2):S354-S.PubMedPubMedCentral
51.
Duntas LH. Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm Metab Res. 2009;41(06):443–7.PubMed
52.
Zoidis E, Seremelis I, Kontopoulos N, Danezis GP. Selenium-dependent antioxidant enzymes: actions and properties of selenoproteins. Antioxidants. 2018;7(5):66-.PubMedPubMedCentral
53.
Metere A, Frezzotti F, Graves CE, Vergine M, De Luca A, Pietraforte D, et al. A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery. Cancer Cell Int. 2018;18(1):1–8.
54.
55.
Brenneisen P, Steinbrenner H, Sies H. Selenium, oxidative stress, and health aspects. Mol Aspects Med. 2005;26(4–5):256–67.PubMed
56.
Li T, Xu H. Selenium-containing nanomaterials for cancer treatment. Cell Reports Physical Science. 2020;1(7):100111.
57.
Vahidi H, Barabadi H, Saravanan M. Emerging selenium nanoparticles to combat cancer: a systematic review. J Cluster Sci. 2020;31:301–9.
58.
Radomska D, Czarnomysy R, Radomski D, Bielawska A, Bielawski K. Selenium as a bioactive micronutrient in the human diet and its cancer chemopreventive activity. Nutrients. 2021;13(5):1649.PubMedPubMedCentral
Metadata
Title
The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial
Authors
Sepide Amini
Marjan Golshani
Masoud Moslehi
Somayeh Hajiahmadi
Gholamreza Askari
Bijan Iraj
Mohammad Bagherniya
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Trials / Issue 1/2023
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-023-07470-2

Other articles of this Issue 1/2023

Trials 1/2023 Go to the issue

Study protocol

Goals for Adherence with Low-cost Incentives (GOALS): a protocol for a randomized controlled trial evaluating the impact of small airtime incentives on ART adherence among young people living with HIV in Kampala, Uganda

Study protocol

Treatment of haemorrhoids: rubber band ligation or sclerotherapy (THROS)? Study protocol for a multicentre, non-inferiority, randomised controlled trial

Study protocol

Dual tracer navigation for lymph node dissection in laparoscopic radical gastrectomy (DANCE trial): a protocol for a prospective, randomized clinical trial

Study protocol

Dry suction versus wet suction technique of endoscopic ultrasound-guided fine-needle biopsy for diagnosis of solid pancreatic lesions: study protocol of a multicenter randomized controlled non-inferiority trial

Study protocol

Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial

Study protocol

The effects of an e-health brisk walking intervention in increasing moderate-to-vigorous physical activity in physically inactive older people with cognitive frailty: study protocol for a randomized controlled trial